Open AccessNegative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and а literature review
Author(s) -
А. А. Румянцев
Publication year - 2021
Publication title -
zlokačestvennye opuholi
Language(s) - English
Resource type - Journals
eISSN - 2587-6813
pISSN - 2224-5057
DOI - 10.18027/2224-5057-2021-11-1-5-8
Subject(s) - medicine , vaccination , immunotherapy , immunology , christian ministry , ovarian cancer , immunity , cancer immunotherapy , cancer , oncology , virology , immune system , philosophy , theology
Gam-COVID-Vac (Sputnik V, Gamaleya Research Institute of Epidemiology and Microbiology of Ministry of Health of Russian Federation) is an adenovirus viral vector vaccine for COVID-19 which became the very first vaccine against SARS-CoV-2 registered in Russia and worldwide. The vaccine efficacy and safety in cancer patients is unknown. We present a clinical case of the absence of post-vaccination immunity after the use of Gam-COVID-Vac in a patient with advanced ovarian cancer treated with maintenance targeted and immunotherapy and discuss it in the light of the available evidence base on the effectiveness of other anti-SARS CoV-2 vaccines in cancer patients.